(Q44583427)

4 December 2017

title

Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study (English)

1 reference

4 December 2017

1 reference

Soo Hyung Ryu

1

1 reference

4 December 2017

Young-Hwa Chung

2

1 reference

4 December 2017

Min Hee Choi

3

1 reference

4 December 2017

Jeong A Kim

4

1 reference

4 December 2017

Jung Woo Shin

5

1 reference

4 December 2017

Myoung Kuk Jang

6

1 reference

4 December 2017

Neung Hwa Park

7

1 reference

4 December 2017

Han Chu Lee

8

1 reference

4 December 2017

Yung Sang Lee

9

1 reference

4 December 2017

Dong Jin Suh

10

1 reference

4 December 2017

publication date

1 October 2003

1 reference

4 December 2017

published in

Journal of Hepatology

1 reference

4 December 2017

volume

39

1 reference

4 December 2017

issue

4

1 reference

4 December 2017

page(s)

614-619

1 reference

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

Dynamics of hepatitis B virus infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

Determination of hepatitis B virus DNA in serum using the polymerase chain reaction: clinical significance and correlation with serological and biochemical markers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

1 reference

7 January 2021

Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

Is lamivudine effective on precore/core promoter mutants of hepatitis B virus?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900394-5

7 January 2021

10.1016/S0168-8278(03)00394-5

Identifiers

DOI

1 reference

4 December 2017

1 reference